Anistreplasi is used in the thrombolytic treatment of coronary arteries. The use of this medication must be practiced under close medical supervision, specifically regarding the monitoring of blood coagulation parameters.

What is Anistreplasi?

Anistreplasi belongs to the category of fibrinolytic drugs as urokinase, Streptokinase and plasminogen activators. Fibrinolytic drugs are able to stimulate the formation of plasmin, an enzyme that protects the body from the blocking of blood vessels, as it can destroy some structures present in the blood like fibrin (protein used in blood clotting) and blood clots (solid masses formed by fibrin, platelets, white blood cells and red blood cells, which can form in the blood vessels). The human body does not directly produce plasmin, but its inactive precursor, plasminogen, which is then used by various substances. In particular, the anistreplasi consists of purified human plasminogen Streptokinase. It is a long-term used thrombolytic drug.

How should Anistreplasi be taken?

Anistreplasi is administered intravenously.

Side effects associated with Anistreplasi

The main side effects caused by the use of this active ingredient include bleeding, which can also appear in the case of simultaneous intake of other anticoagulants or in the case of overdosing.

Contraindications and warnings associated with the use of Anistreplasi

It is not suitable for patients with severe hypertension and vascular diseases, also to patients who have haemorrhagic bleeding risk and generally in situations where the risk of haemorrhage is high.